Novel hydroxamic acid-related phosphinates: inhibition of neutral aminopeptidase N (APN).

Here we describe the inhibitory activity toward neutral aminopeptidase of three new families of phosphinate inhibitors related in structure to hydroxamic acids. These compounds, even as racemic mixtures, are good inhibitors of APN and show strong structure activity relationship (SAR) depending on the substituents in P1 and P1' positions.

[1]  A. Jeng,et al.  The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. , 2004, Current medicinal chemistry.

[2]  J. Oleksyszyn,et al.  Synthesis of α1-(Cbz-aminoalkyl)-α2-(hydroxyalkyl)phosphinic esters , 2005 .

[3]  Seth M. Cohen,et al.  Heterocyclic zinc-binding groups for use in next-generation matrix metalloproteinase inhibitors: potency, toxicity, and reactivity , 2006, JBIC Journal of Biological Inorganic Chemistry.

[4]  R. Wahl,et al.  Relationship between structure and bioavailability in a series of hydroxamate based metalloprotease inhibitors , 1995 .

[5]  P. Tucker,et al.  Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates , 2006 .

[6]  P. Bartlett,et al.  Phosphorus amino acid analogues as inhibitors of leucine aminopeptidase. , 1987, Journal of medicinal chemistry.

[7]  Sherry L. Niessen,et al.  Proteomic profiling of metalloprotease activities with cocktails of active-site probes , 2006, Nature chemical biology.

[8]  W. Bode,et al.  Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor. , 1995, Biochemistry.

[9]  J. Oleksyszyn,et al.  Facile Synthesis of bis‐α‐Aminoalkylphosphinates , 2006 .

[10]  A. Gearing,et al.  Design and therapeutic application of matrix metalloproteinase inhibitors. , 1999, Chemical reviews.

[11]  B. Bauvois,et al.  Aminopeptidase‐N/CD13 (EC 3.4.11.2) inhibitors: Chemistry, biological evaluations, and therapeutic prospects , 2005, Medicinal research reviews.